Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

Sh, Hofma; Pc, Smits; Brouwer, Jan; Ma, Velders; Aw, van Toorenenbergen; Quéré, Michel; Cj, de Vries; Aj, van Boven

doi:10.4244/eijy15m01_03

Cited by 23 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefit of DESs, however, is limited to short‐term outcomes because of extremely late stent thrombosis in DESs, especially in first‐generation DESs in populations with CKD or high bleeding risk . In addition, no significant difference in long‐term outcomes among first‐generation DESs, second‐generation DESs, and BMSs was found. Moreover, these studies included small population sizes and presented conflicting findings.…”

Section: Introductionmentioning

confidence: 98%

Comparison of Drug‐Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta‐Analysis

Tang

Zhang

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundDrug‐eluting stents (DESs) and bare metal stents (BMSs) are both recommended to improve coronary revascularization and to treat coronary artery disease in patients with chronic kidney disease (CKD). However, the potential superiority of DESs over BMSs for reducing the incidence of long‐term major adverse cardiovascular events and mortality in CKD patients has not been established, and the results remain controversial. We aimed to systematically assess and quantify the total weight of evidence regarding the use of DESs versus BMSs in CKD patients.Methods and ResultsIn this systematic review and conventional meta‐analysis, electronic studies published in any language until May 20, 2016, were systematically searched through PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. We included randomized controlled trials and observational studies comparing outcomes in CKD patients with DESs versus BMSs and extracted data in a standard form. Pooled odd ratios and 95% CIs were calculated using random‐ and fixed‐effects models. Finally, 38 studies involving 123 396 patients were included. The use of DESs versus BMSs was associated with significant reductions in major adverse cardiovascular events (pooled odds ratio 0.75; 95% CI, 0.64–0.88; P<0.001), all‐cause mortality (odds ratio 0.81; 95% CI, 0.73–0.90; P<0.001), myocardial infarction, target‐lesion revascularization, and target‐vessel revascularization. The superiority of DESs over BMSs for improving clinical outcomes was attenuated in randomized controlled trials.ConclusionsThe use of DESs significantly improves the above outcomes in CKD patients. Nevertheless, large‐sized randomized controlled trials are necessary to determine the real effect on CKD patients and whether efficacy differs by type of DES.

show abstract

Section: Introductionmentioning

confidence: 98%

Comparison of Drug‐Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta‐Analysis

Tang

Zhang

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…Although SESs and PESs are not available at present, the present study would be useful for anticipating the outcomes of patients continuously treated at outpatients with first-generation DESs. In addition, since Hofma et al [19], reported that the event rate at 3 years was not significantly different between first (SES)-and second (everolimus-eluting stent; EES)-generation DES for acute myocardial infarction. Therefore, we could also participate the outcomes of the currently available EES as similar as the SES, the former (no-longer used) DES.…”

Section: Discussionmentioning

confidence: 97%

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Miyamoto

Ishikawa

Nakano

et al. 2016

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

We conducted a retrospective examination of the very long-term outcomes of placing sirolimus (SES) and paclitaxel (PES)-eluting stents in patients with ST-elevation myocardial infarction (STEMI). This was a nonrandomized, retrospective, single-center study that included 872 first STEMI patients who underwent successful placement of either SES (n = 547) or PES from November 2004 to April 2012. The primary end point was the incidence of severe cardiac events comprising cardiac death, nonfatal recurrent myocardial infarction, and definite stent thrombosis (ST). The frequency of target lesion revascularization (TLR) was also compared. A propensity score-matched analysis was used to adjust the 29 baseline variables. In the baseline-adjusted cohorts in 231 STEMI patients in each arm, the frequency of the primary end point in the SES group (5.6 %) during the follow-up duration of 2583 ± 806 days was not significantly different from that in the PES group (6.1 %, follow-up: 1866 ± 699 days). The cumulative primary end point-free ratio in the SES group was not significantly different from that in the PES group (p = 0.503). The frequency of TLR in the SES group (7.5 %) was significantly lower than that in the PES group (16.9 %, p = 0.005), with and the significantly higher cumulative TLR-free ratio in the SES group than that in the PES group (p < 0.001). The very long-term clinical outcomes after SES or PES placement for STEMI patients were statistically equivalent. SES showed the better angiographic outcomes for STEMI compared to PES.

show abstract

“…AMI is a serious coronary heart condition and AMI-associated ventricular remodeling is an important factor reducing the quality of life and survival rate of affected patients (15). The broad concept of AMI-associated ventricular remodeling implies that AMI is impacted by haemodynamics and non-haemodynamics, resulting in changes in heart size, shape and ultrastructure as well as damage of heart function (16).…”

Section: Discussionmentioning

confidence: 99%

Gambogic acid exerts cardioprotective effects in a rat model of acute myocardial infarction through inhibition of inflammation, iNOS and NF‑κB/p38 pathway

et al. 2017

View full text Add to dashboard Cite

Abstract. Gamboge, the dried resin secreted by Garcinia maingayii (gambogic tree), was previously demonstrated to exert anti-inflammatory effects. The present study examined the effects of gambogic acid, the major active constituent of gamboge, on myocardial infarction (MI) and inflammation in a rat model and explored the possible underlying mechanisms. The results demonstrated that gambogic acid inhibited the ratio of heart weight to body weight and myocardial damage (via lactate dehydrogenase and cardiac troponin T) in rats with MI. Gambogic acid suppressed the activation of interleukin (IL)-6 and tumor necrosis factor-α, and increased IL-10 levels in MI rats. Furthermore, gambogic acid reduced inducible nitric oxide synthase (iNOS), matrix metalloproteinase (MMP)-2, MMP-9, intercellular adhesion molecule-1 (ICAM-1), nuclear factor (NF)-κB/p65 and phosphorylated p38 protein in ischemic myocardial tissue of MI rats. In conclusion, gambogic acid exerted anti-inflammatory effects in MI rats by targeting the iNOS, MMPs, ICAM-1, NF-κB and p38 pathways. Gambogic acid may protect against MI-induced inflammation in rats, which may be associated with the activation of the NF-κB/p38 pathway.

show abstract

Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

Cited by 23 publications

References 6 publications

Comparison of Drug‐Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta‐Analysis

Comparison of Drug‐Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta‐Analysis

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Gambogic acid exerts cardioprotective effects in a rat model of acute myocardial infarction through inhibition of inflammation, iNOS and NF‑κB/p38 pathway

Contact Info

Product

Resources

About